Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NMI’s Top 10 Health Trends

This article was originally published in The Tan Sheet

Executive Summary

Market-wise manufacturers will expand nutritional supplements offerings into new formats beyond capsules, and condition-specific supplements will gain momentum with clinical science to support the products' claims, according to the Natural Marketing Institute predictions for the "Top 10 Health & Wellness Trends for 2006." The Harleysville, Penn.-based consulting group's list also identifies personalized supplements as an emerging trend as consumers look for more individualized approaches to health such as USDA's "MyPyramid" program released last April (1"The Tan Sheet" April 25, 2005, p. 18). The firm also cites shifting demographics as dictating market developments as well as corporate social responsibility creating brand loyalty to play roles in the 2006 health and wellness sector...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099265

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel